Business Context and Reporting Period
Company: Anika Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1999
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for bone, cartilage, and soft tissue repair. Key products include ORTHOVISC (human osteoarthritis), HYVISC (equine osteoarthritis), and AMVISC (ophthalmic surgery viscoelastics manufactured for Bausch & Lomb). The company is also developing INCERT (adhesion prevention) and OSSIGEL (bone fracture healing).
Key Financial Metrics (Year Ended Dec 31, 1999)
| Metric | 1999 (Restated) | 1998 (Restated) |
|---|---|---|
| Total Revenue | $13,483,000 | $13,273,000 |
| Gross Profit | $7,042,000 | $7,259,000 |
| Operating Expenses | $7,184,000 | $4,687,000 |
| Net Income (Loss) | $(2,496,000) | $3,752,000 |
| Diluted EPS | $(0.24) | $0.34 |
| Cash & Cash Equivalents | $6,441,000 | $10,713,000 |
| Total Investments | $13,743,000 | $12,008,000 |
| Working Capital | $18,973,000 | $26,480,000 |
| Accumulated Deficit | $(4,773,000) | $(2,277,000) |
Liquidity: The company held approximately $20.2 million in cash, cash equivalents, and investments as of December 31, 1999. Management believes this is sufficient to fund operations through December 2001.
Material Changes vs. Prior Period
- Accounting Restatement: The company restated 1998 and Q1-Q3 1999 results following an SEC inquiry regarding revenue recognition for ORTHOVISC sales to Zimmer, Inc. This resulted in a $3.625 million cumulative charge in Q1 1999, turning a projected profit into a net loss for the year.
- Revenue Recognition Policy: Revenue from Zimmer is now recognized at shipment based on minimum contract prices rather than estimated average selling prices. Upfront licensing fees are now amortized over the contract term (10 years) rather than recognized immediately.
- Operating Expenses: Research and Development (R&D) expenses surged by 112% to $4.15 million, primarily due to costs associated with the Phase III clinical trial for ORTHOVISC.
- Product Revenue: Product revenue increased 11.1% to $13.08 million, driven by a 22% increase in ORTHOVISC sales and a 3.7% increase in AMVISC sales.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
- ORTHOVISC Clinical Trial: The Phase III trial in the U.S. and Canada completed patient enrollment in August 1999, with the final follow-up completed in February 2000. Statistical analysis was pending at the time of filing. FDA approval is required for U.S. commercialization.
- Manufacturing: The company is expanding its Woburn, MA facility to meet demand through 2003.
- Stock Repurchase: The company repurchased 762,100 shares for approximately $3.87 million under a $4 million authorization program.
Risks and Contingencies
- Customer Concentration: Bausch & Lomb Surgical accounted for 63.9% of product revenue in 1999. The supply contract expires in 2001, with no assurance of renewal or favorable terms.
- Zimmer Distribution Agreement: Zimmer's sales of ORTHOVISC failed to meet minimums for 1998 and are expected to miss 1999 minimums. This gives Zimmer the right to terminate the contract, which would materially impact future revenue.
- Regulatory Risk: ORTHOVISC is currently limited to investigational use in the U.S. Failure to obtain FDA approval by January 1, 2001, could trigger contract termination with Zimmer.
- Patent Interference: A third party is attempting to provoke a patent interference regarding the INCERT product, which could jeopardize future marketing rights.
Investor Verification Checklist
- Restatement Impact: Verify the long-term implications of the revenue recognition change on future earnings recognition from Zimmer.
- Zimmer Contract Status: Monitor whether Zimmer exercises its right to terminate the distribution agreement due to missed sales minimums in 1998 and 1999.
- FDA Approval Timeline: Track the statistical analysis results of the ORTHOVISC Phase III trial and the subsequent PMA submission/approval status.
- Bausch & Lomb Renewal: Assess the likelihood of contract renewal for AMVISC manufacturing beyond the December 31, 2001 expiration date.
- Cash Burn Rate: Confirm that the $20.2 million cash position remains sufficient given the high R&D spend and potential loss of Zimmer revenue.